-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Shenzhen Bioeasy Sees Lower 2022 Net Profit, Shrinking Margin On COVID Test Products

Reuters · 01/06/2023 05:54
BRIEF-Shenzhen Bioeasy Sees Lower 2022 Net Profit, Shrinking Margin On COVID Test Products

- Shenzhen Bioeasy Biotechnology Co Ltd 300942.SZ:

  • SAYS IT SEES 2022 NET PROFIT DOWN 36.6-53.5% Y/Y FROM 236.5 MILLION YUAN ($34.46 million)

  • SAYS PROFIT MARGIN FOR COVID TEST KIT PRODUCTS SAW LARGE DECLINE

Source text

Further company coverage: 300942.SZ


($1 = 6.8622 Chinese yuan renminbi)


(Reporting by Hong Kong )

((meg.shen@thomsonreuters.com; 852-39525805;))